Accuray (ARAY) Expected to Announce Quarterly Earnings on Wednesday

Accuray (NASDAQ:ARAY) is anticipated to announce its Q3 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $111.90 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11). The business had revenue of $102.24 million during the quarter, compared to the consensus estimate of $100.86 million. Accuray had a negative return on equity of 59.81% and a negative net margin of 8.15%.

Accuray Trading Down 1.4%

ARAY stock opened at $0.46 on Tuesday. The company has a market cap of $54.65 million, a price-to-earnings ratio of -1.59 and a beta of 1.43. The company has a quick ratio of 0.71, a current ratio of 1.47 and a debt-to-equity ratio of 2.34. The business has a fifty day simple moving average of $0.45 and a 200-day simple moving average of $0.80. Accuray has a 52 week low of $0.33 and a 52 week high of $2.10.

Analyst Ratings Changes

A number of analysts have recently commented on ARAY shares. Wall Street Zen downgraded Accuray from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. BTIG Research lowered their price target on Accuray from $4.00 to $2.00 and set a “buy” rating for the company in a report on Thursday, February 5th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $2.00.

Institutional Trading of Accuray

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in Accuray in the 4th quarter valued at $137,000. Invesco Ltd. boosted its position in Accuray by 52.7% in the 4th quarter. Invesco Ltd. now owns 245,000 shares of the medical equipment provider’s stock valued at $202,000 after buying an additional 84,528 shares during the last quarter. Mackenzie Financial Corp boosted its position in Accuray by 76.5% in the 4th quarter. Mackenzie Financial Corp now owns 1,918,086 shares of the medical equipment provider’s stock valued at $1,538,000 after buying an additional 831,220 shares during the last quarter. Oxford Asset Management LLP purchased a new position in Accuray in the 4th quarter valued at about $44,000. Finally, Bridgeway Capital Management LLC boosted its position in Accuray by 34.8% in the 4th quarter. Bridgeway Capital Management LLC now owns 174,425 shares of the medical equipment provider’s stock valued at $144,000 after buying an additional 45,025 shares during the last quarter. 64.08% of the stock is currently owned by institutional investors and hedge funds.

About Accuray

Accuray Incorporated (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.

Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.